Actively Recruiting
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-12-03
876
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.
CONDITIONS
Official Title
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation and written informed consent
- Age between 18 and 75 years, any gender
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Life expectancy of at least 3 months
- Pathologically confirmed advanced solid tumor
- Ability to provide fresh or archived tumor tissue
- At least one measurable tumor lesion according to RECIST v1.1
- Adequate bone marrow reserve and organ function
- Use of contraception during the trial and negative pregnancy test for women of childbearing potential within 7 days before first dose
You will not qualify if you...
- History or symptoms of meningeal or central nervous system metastasis
- Previous or concurrent other malignancies
- Untreated spinal cord compression
- Uncontrolled tumor-related pain
- Previous antibody-coupled drug therapy with topoisomerase I inhibitor toxin or EGFR/c-Met double antibody
- Received systemic antitumor therapy before first dose
- Major surgery other than diagnosis or biopsy within 28 days before dosing; minor surgery within 7 days before dosing
- Prior radiation therapy exceeding prescribed dose before study treatment
- Use of other investigational drugs within 4 weeks before study treatment
- Unresolved grade 3 or higher toxicities from prior anticancer therapy
- History of interstitial or non-infectious pneumonia
- Uncontrolled pleural or pericardial effusion; moderate or severe symptomatic ascites
- Intestinal obstruction or symptoms within 6 months before dosing
- Poorly controlled or severe cardiovascular disease
- Active hepatitis B or C infection
- History of immunodeficiency
- Severe infection within 30 days before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-Sen university cancer center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
R
Rongfu Mao, MD
CONTACT
H
Hao Shen, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here